In 2023, a significant legal victory unfolded when Masimo Corporation successfully argued that Apple had infringed upon its patents through Apple Watch technology. This ruling led to the International Trade Commission (ITC) imposing a ban on the importation of certain Apple Watch models deemed to violate Masimo’s intellectual property. However, in a recent development, Apple adapted its technology, enabling the company to continue selling Apple Watch models in the U.S. market.
ITC Says Apple Watch Does Not Infringe on Masimo Patents
The latest ruling from ITC Administrative Law Judge Monica Bhattacharyya determined that the Apple Watch, in its updated iteration, does not infringe upon any of Masimo’s patents. This decision is pivotal for Apple, allowing the tech giant to maintain its sales of the Apple Watch within the United States. The legal dispute had been ongoing for years, with Masimo initially claiming that the device violated multiple patents related to blood oxygen monitoring technology.
To navigate through the legal complexities, Apple made notable alterations to the Apple Watch software. Initially, the company disabled the blood oxygen sensing feature to satisfy the requirements of U.S. Customs and Border Protection, allowing the watch to resume sales. Subsequently, Apple altered the functionality so that the processing of blood oxygen data would occur on an iPhone rather than directly on the Apple Watch itself. These adjustments were crucial in achieving the recent favorable ruling.
In a statement to 9to5Mac, an Apple spokesperson expressed gratitude, stating, “We thank the Administrative Law Judge for her careful consideration and are pleased with the decision. For six years, Masimo has brought dozens of false claims against Apple, nearly all of which have been rejected. We will continue innovating to create industry-leading health, wellness, and life-saving features for our users.”
It’s Not Over Yet
While the recent ruling allows Apple to continue selling its current version of the Apple Watch, it also firmly establishes that Apple cannot revert to the prior method of blood oxygen sensing conducted on the watch itself. This restriction maintains the precedent set by the United States Court of Appeals for the Federal Circuit, which upheld the initial ITC decision from 2023.
As a reminder, to bypass the initial ban, Apple had first disabled the blood oxygen feature before implementing a system shift for processing data to iPhones. The Court of Appeals’ affirmation of the original ruling means that Apple must adhere to the current design. Nonetheless, users won’t experience significant changes, as the watch still needs to be paired with an iPhone for functionality.
Despite the positive outcome for Apple, the company has indicated it may pursue further legal avenues. “We disagree with this decision and are evaluating all avenues for further review. We innovate every day to develop industry-leading health, wellness, and safety features and will continue working to provide our users the best products and services in the world,” an Apple representative noted.
For those seeking more information on the legal developments regarding the Apple Watch and Masimo’s patents, you can find additional details Here.
Image Credit: www.androidheadlines.com
